Loading
Please wait while we load your information from QuoteMedia.
Loading
Please wait while we load your information from QuoteMedia.
Please wait while we load your information from QuoteMedia.
Please wait while we load your information from QuoteMedia.
Please wait while we load your information from QuoteMedia.
As of June 3, 2025 • 5:01 PM ET
As of June 3, 2025 • 5:01 PM ET
Date/Time | Source | News Release |
---|---|---|
05/14/2025 09:37 PM EDT | SeekingAlpha | Celcuity outlines $2B peak revenue potential for gedatolisib as Phase 3 breast cancer trials progress |
05/14/2025 09:36 PM EDT | SeekingAlpha | Celcuity Inc. (CELC) Q1 2025 Earnings Call Transcript |
05/14/2025 04:05 PM EDT | SeekingAlpha | Celcuity Non-GAAP EPS of -$0.81 beats by $0.05 |
05/14/2025 07:00 AM EDT | US Earnings Reports | Expected US Company Earnings on Wednesday, May 14th, 2025 |
05/14/2025 05:30 AM EDT | US Earnings Reports | Expected earnings - Celcuity Inc. |
05/13/2025 06:48 PM EDT | KlickAnalytics | CELC - Historical Price Movements Surrounding Earnings |
05/13/2025 06:43 PM EDT | KlickAnalytics | CELC - Historical Earnings Price Analysis |
03/31/2025 10:51 PM EDT | SeekingAlpha | Celcuity projects $2B revenue potential for gedatolisib in second-line breast cancer market |
03/31/2025 10:50 PM EDT | SeekingAlpha | Celcuity Inc. (CELC) Q4 2024 Earnings Call Transcript |
03/31/2025 04:03 PM EDT | SeekingAlpha | Celcuity GAAP EPS of -$0.85 misses by $0.14 |
Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.